Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Illumina broadens cancer profiling portfolio

Illumina : 11 April, 2008  (New Product)
Illumina is introducing three new product solutions for cancer research that include expansion of Illumina's proprietary DASL Assay to whole-genome profiling.
The company has also launched DASL focused expression and methylation profiling on Illumina's VeraCode technology.

The new solutions allow researchers to apply synergies across Illumina technology platforms to better understand the complex molecular mechanisms that give rise to cancer.

Illumina's DASL Assay was specifically designed to successfully profile expression in degraded RNA, such as that found in formalin-fixed paraffin embedded (FFPE) samples. At the Dana-Farber Cancer Institute researchers are using whole-genome DASL profiling to identify molecular profiles associated with chemotherapy resistance in ovarian cancer.

'We have a significant number of archived ovarian cancer samples, and this new approach has provided me with a way to finally access the information in these invaluable samples,' said Dr John Quackenbush. 'The DASL Assay gives us the ability to obtain consistent, high-quality data from FFPE samples and has opened-up new avenues of investigation that were not previously available to us.'

Finally, using Illumina's GoldenGate Assay for Methylation with the VeraCode technology, researchers can now uncover epigenetic modifications in DNA that have significant and widespread effects on gene expression. Researchers from the University of Connecticut Health Center have used both the BeadArray and VeraCode technologies to examine splice variants.

'Most researchers use their genome-wide array to find the 100 to 500 genes of interest and then build a lower-complexity pool to run on a larger number of samples. I simply moved the same Assay over to the VeraCode platform, which used an identical workflow and required no additional design. Reproducibility of data was very high between the two platforms,' said Dr Brenton Gravely.

'The DASL gene expression and GoldenGate Methylation assays offered across both the BeadArray and VeraCode facilitate the understanding of the molecular basis of cancer,' said Tristan Orpin, senior vice president of Illumina's Commercial Operations.

'Researchers will need to investigate changes in RNA expression, epigenetic control, and coding and non-coding regions of the genome. Illumina's new solutions for RNA profiling and methylation will enable researchers to study and validate these changes with a common assay.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo